Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

PURPOSE: The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance. The genes that associated with cisplatin resistance remain unclear. Herein, we aimed to identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zhen-duo, Hao, Lin, Han, Xiao-xiao, Wu, Zhuo-Xun, Pang, Kun, Dong, Yang, Qin, Jia-xin, Wang, Guang-yue, Zhang, Xuan-ming, Xia, Tian, Liang, Qing, Zhao, Yan, Li, Rui, Zhang, Shao-qi, Zhang, Jun-hao, Chen, Jian-gang, Wang, Gong-cheng, Chen, Zhe-Sheng, Han, Cong-hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819945/
https://www.ncbi.nlm.nih.gov/pubmed/35130920
http://dx.doi.org/10.1186/s12943-022-01517-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819945/
https://www.ncbi.nlm.nih.gov/pubmed/35130920
http://dx.doi.org/10.1186/s12943-022-01517-9

Ejemplares similares